$1.32
5.60% day before yesterday
NYSE, Aug 22, 10:00 pm CET
ISIN
US7133171055
Symbol
PEPG

PepGen Stock price

$1.32
-0.08 5.71% 1M
-0.97 42.36% 6M
-2.47 65.17% YTD
-8.39 86.41% 1Y
-8.31 86.29% 3Y
-11.57 89.76% 5Y
-11.57 89.76% 10Y
-11.57 89.76% 20Y
NYSE, Closing price Fri, Aug 22 2025
+0.07 5.60%
ISIN
US7133171055
Symbol
PEPG
Industry

Key metrics

Basic
Market capitalization
$43.3m
Enterprise Value
$-31.4m
Net debt
positive
Cash
$74.7m
Shares outstanding
32.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.3
P/B
0.6
Financial Health
Equity Ratio
78.6%
Return on Equity
-75.9%
ROCE
-119.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-101.3m | $-110.1m
EBIT
$-102.8m | $-115.2m
Net Income
$-96.9m | $-101.5m
Free Cash Flow
$-90.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-7.3% | -14.5%
EBIT
-7.3% | -17.9%
Net Income
-8.7% | -12.8%
Free Cash Flow
-20.4%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-3.0
FCF per Share
$-2.8
Short interest
7.2%
Employees
62
Rev per Employee
$0.0
Show more

Is PepGen a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

PepGen Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a PepGen forecast:

9x Buy
82%
1x Hold
9%
1x Sell
9%

Analyst Opinions

11 Analysts have issued a PepGen forecast:

Buy
82%
Hold
9%
Sell
9%

Financial data from PepGen

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 22 22
16% 16%
-
- Research and Development Expense 80 80
5% 5%
-
-101 -101
7% 7%
-
- Depreciation and Amortization 1.48 1.48
2% 2%
-
EBIT (Operating Income) EBIT -103 -103
7% 7%
-
Net Profit -97 -97
9% 9%
-

In millions USD.

Don't miss a Thing! We will send you all news about PepGen directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PepGen Stock News

Neutral
Business Wire
13 days ago
NEW YORK--(BUSINESS WIRE)---- $PEPG #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) and reminds investors of the August 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a ...
Neutral
GlobeNewsWire
16 days ago
Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In PepGen (PEPG) To Contact Them Directly To Discuss Their Options
Neutral
GlobeNewsWire
16 days ago
Investors can contact the law firm at no cost to learn more about recovering their losses
More PepGen News

Company Profile

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.

Head office United States
CEO James McArthur
Employees 62
Founded 2018
Website pepgen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today